SECsense Logo

Bellevue Life Sciences Acquisition Corp: Key Insights from 8-K Filing (Jan 9, 2025)

$BLAC
Form 8-K
Filed on: 2025-01-10
Source
Bellevue Life Sciences Acquisition Corp: Key Insights from 8-K Filing (Jan 9, 2025)

The extracted information from the financial report indicates the following key points:

  1. Entity Information:
  • Name: Bellevue Life Sciences Acquisition Corp.
  • CIK: 0001840425 (Central Index Key used by the SEC).
  • Incorporation: Delaware.
  • Address: 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004.
  • Phone Number: (425) 635-7700.
  1. Filing Type and Date:
  • Filing Type: 8-K (Current report used to disclose important events).
  • Filing Date: January 9, 2025.
  1. Stock and Securities Information:
  • Units Offered: Each unit consists of:
    • One Share of Common Stock (Ticker: BLACU, NASDAQ).
    • One Redeemable Warrant (Ticker: BLAC, NASDAQ) exercisable for shares of common stock at an exercise price of $11.50 per share.
    • One Right (Ticker: BLACW, NASDAQ) to receive one-tenth (1/10) of one share of common stock.
  1. Par Value: The common stock has a par value of $0.0001 per share.
  2. Financial Context:
  • The report specifies that the information pertains to the end date of January 9, 2025, indicating that the financial condition or securities structure is being reported as of that specific date.
  1. Segment Information: The report discusses various segments related to the classes of stock, including:
  • Common Stock.
  • Redeemable Warrants.
  • Rights to receive fractional shares of common stock.

Insights:

  • The filing is significant for investors as it outlines the structure of the units being offered by Bellevue Life Sciences Acquisition Corp, which combines common stock with warrants and rights.
  • The specific exercise price of the warrants ($11.50) is a critical detail for potential investors assessing the investment's value.
  • The combination of common stock, redeemable warrants, and rights enhances the investment attractiveness by providing multiple avenues for potential returns.

Overall, this financial report provides essential details about a securities offering and the associated rights, crucial for investors and analysts in evaluating the investment opportunity.